Ignite Creation Date:
2024-05-05 @ 6:46 PM
Last Modification Date:
2024-10-26 @ 9:36 AM
Study NCT ID:
NCT00540436
Status:
COMPLETED
Last Update Posted:
2012-10-15
First Post:
2007-10-05
Brief Title:
Evaluate the Efficacy Safety and Pharmacokinetics of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
Study AMB107816 Clinical Evaluation of GSK1325760A in the Treatment of Pulmonary Arterial Hypertension PAH- An Open-Label Phase IIIII Study to Evaluate the Efficacy Safety and Pharmacokinetics of GSK1325760A -Classification Exploratory and Confirmatory Clinical Trial
Status:
COMPLETED
Status Verified Date:
2012-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective of this study is to evaluate the effect of GSK1325760A on improvement in exercise capacity in subjects with pulmonary arterial hypertension PAH
The secondary objectives of this study are to evaluate administration of GSK1325760A on
The safety and tolerability
Improvement of PAH
The steady-state plasma pharmacokinetics of GSK1325760A
The secondary objectives of this study are to evaluate administration of GSK1325760A on
The safety and tolerability
Improvement of PAH
The steady-state plasma pharmacokinetics of GSK1325760A
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None